Nasdaq

Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure

Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without ...
Business Wire

Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor ...
Medicine Buffalo

UB’s dental implant center receives prestigious international recognition

BUFFALO, N.Y. — The Buhite-DiMino Center for Implant Dentistry and Advanced Dental Education at the University at Buffalo School of Dental Medicine has been named an international scholarship center ...
Medicine Buffalo

UB’s dental implant center named ITI scholarship center

The Buhite-DiMino Center for Implant Dentistry and Advanced Dental Education in the School of Dental Medicine has been named an international scholarship center by the International Team for ...